secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-08-25T21:12:15+00:00
Accession:  0001493152-26-040080
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce gets Nasdaq extension on bid price; Cy deal triggers initial listing review
--------------------------------------------------------------------------------

- Nasdaq confirmed compliance with $2.5M stockholders' equity (Rule 5550(b)(1)) but requires evidence in next periodic report or delisting.
- Bid price cure deadline extended to Feb 22, 2027; stock had been below $1.00 for 30 consecutive days.
- Cy Biopharma acquisition deemed a Change of Control under Nasdaq Rule 5110(a); company must satisfy initial listing criteria.
- Ensysce intends to submit an initial listing application to complete the Cy transaction and convert preferred shares.
- Failure to meet listing requirements could lead to trading suspension of ENSC common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226040080/0001493152-26-040080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226040080/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-040080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer